Cystatin C is a good predictor of hepatorenal syndrome and survival in patients with cirrhosis who have normal serum creatinine levels

Hepato-Gastroenterology

Volumn 59, Issue 116, 2012, Pages 1168-1173

  Ahn, Hyung Su ^a   Kim, Young Seok ^a   Kim, Sang Gyune ^a   Kim, Hyung Ki ^b   Min, Seul Ki ^c   Jeong, Soung Won ^a   Jang, Jae Young ^a   Lee, Sae Hwan ^a   Kim, Hong Soo ^a   Kim, Boo Sung ^a   Park, Jung Mi ^a  

^a Soonchunhyang University College of Medicine   (South Korea)

^b Korea Worker's Compensation and Welfare Service   (South Korea)

^c Digestive Disease Center   (South Korea)

Author keywords

Creatinine; Cystatin C; Hepatorenal syndrome; Liver cirrhosis

Indexed keywords

CREATININE; CYSTATIN C; SODIUM;

ADULT; ARTICLE; CREATININE BLOOD LEVEL; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEPATITIS B; HEPATITIS C; HEPATORENAL SYNDROME; HUMAN; KIDNEY FUNCTION; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTHROMBIN TIME; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SODIUM BLOOD LEVEL; SURVIVAL; SURVIVAL PREDICTION; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; BIOLOGICAL MARKERS; CREATININE; CYSTATIN C; FEMALE; GLOMERULAR FILTRATION RATE; HEPATORENAL SYNDROME; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84861411819     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge11616     Document Type: Article

References (36)

1. Garcia-Tsao G, Parikh CR, Viola A: Acute kidney injury in cirrhosis. Hepatology 2008; 48:2064-2077.
2. Arroyo V, Colmenero J: Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol 2003; 38Suppl1:S69-89.
3. Shellman RG, Fulkerson WJ, DeLong E, Piantadosi CA: Prognosis of patients with cirrhosis and chronic liver disease admitted to the medical intensive care unit. Crit Care Med 1988; 16:671-678.
4. Arroyo V, Gines P, Gerbes AL, et al.: Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996; 23:164-176.
5. Gerbes AL, Gulberg V, Bilzer M, Vogeser M: Evaluation of serum cystatin C concentration as a marker of renal function in patients with cirrhosis of the liver. Gut 2002; 50:106-110.
6. Arroyo V, Fernandez J, Gines P: Pathogenesis and treatment of hepatorenal syndrome. Semin Liver Dis 2008; 28:81-95.
7. Cholongitas E, Shusang V, Marelli L, et al.: Review article: renal function assessment in cirrhosis-difficulties and alternative measurements. Aliment Pharmacol Ther 2007; 26:969-978.
8. Randers E, Erlandsen EJ: Serum cystatin C as an endogenous marker of the renal function - a review. Clin Chem Lab Med 1999; 37:389-395.
9. Sjostrom P, Tidman M, Jones I: Determination of the production rate and non-renal clearance of cystatin C and estimation of the glomerular filtration rate from the serum concentration of cystatin C in humans. Scand J Clin Lab Invest 2005; 65:111-124.
10. Demirtas S, Bozbas A, Akbay A, Yavuz Y, Karaca L: Diagnostic value of serum cystatin C for evaluation of hepatorenal syndrome. Clin Chim Acta 2001; 311:81-89.
11. Hagstam KE, Nordenfelt I, Svensson L, Svensson SE: Comparison of different methods for determination of glomerular filtration rate in renal disease. Scand J Clin Lab Invest 1974; 34:31-36.
12. Picciotto G, Cacace G, Cesana P, Mosso R, Ropolo R, De Filippi PG: Estimation of chromium-51 ethylene diamine tetra-acetic acid plasma clearance: a comparative assessment of simplified techniques. Eur J Nucl Med 1992; 19:30-35.
13. Brochner-Mortensen J: A simple method for the determination of glomerular filtration rate. Scand J Clin Lab Invest 1972; 30:271-274.
14. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
15. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-470.
16. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R: Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60:646-649.
17. Wiesner R, Edwards E, Freeman R, et al.: Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124:91-96.
18. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V: Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007; 56:1310-1318.
19. Hanley JA, McNeil BJ: The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143:29-36.
20. Hanley JA, McNeil BJ: A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148:839-843.
21. Gines A, Escorsell A, Gines P, et al.: Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105:229-236.
22. Sanyal AJ, Boyer T, Garcia-Tsao G, et al.: A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008; 134:1360-1368.
23. Fernandez-Esparrach G, Sanchez-Fueyo A, Gines P, et al.: A prognostic model for predicting survival in cirrhosis with ascites. J Hepatol 2001; 34:46-52.
24. Llach J, Gines P, Arroyo V, et al.: Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 1988; 94:482-487.
25. Whelton A, Wastson AJ, Rock RC: Nitrogen metabolites and renal function. In Burtis CA, Ashwood ER, eds. Tietz textbook of clinical chemistry: WB, Saunders; Philadelphia 1994:1513-1575.
26. Caregaro L, Menon F, Angeli P, et al.: Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis. Arch Intern Med 1994; 154:201-205.
27. Sherman DS, Fish DN, Teitelbaum I: Assessing renal function in cirrhotic patients: problems and pitfalls. Am J Kidney Dis 2003; 41:269-278.
28. Cocchetto DM, Tschanz C, Bjornsson TD: Decreased rate of creatinine production in patients with hepatic disease: implications for estimation of creatinine clearance. Ther Drug Monit 1983; 5:161-168.
29. Klopper JF, Hauser W, Atkins HL, Eckelman WC, Richards P: Evaluation of 99m Tc-DTPA for the measurement of glomerular filtration rate. J Nucl Med 1972; 13:107-110.
30. Woitas RP, Stoffel-Wagner B, Flommersfeld S, et al.: Correlation of serum concentrations of cystatin C and creatinine to inulin clearance in liver cirrhosis. Clin Chem 2000; 46:712-715.
31. Arroyo V, Gines P, Jimenez W: Renal dysfunction in cirrhosis. In Bircher L, Benhamou J, McIntyre N, eds. Oxford textbook of clinical hepatology: Oxford University Press; New York 1999:733-764.
32. Simonsen O, Grubb A, Thysell H: The blood serum concentration of cystatin C (gamma-trace) as a measure of the glomerular filtration rate. Scand J Clin Lab Invest 1985; 45:97-101.
33. Grubb A, Simonsen O, Sturfelt G, Truedsson L, Thysell H: Serum concentration of cystatin C, factor D and beta 2-microglobulin as a measure of glomerular filtration rate. Acta Med Scand 1985; 218:499-503.
34. Grubb A: Diagnostic value of analysis of cystatin C and protein HC in biological fluids. Clin Nephrol 1992; 38Suppl1:S20-27.
35. Seo YS, Jung ES, An H, et al.: Serum cystatin C level is a good prognostic marker in patients with cirrhotic ascites and normal serum creatinine levels. Liver Int 2009; 29:1521-1527.
36. Londono MC, Cardenas A, Guevara M, et al.: MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. Gut 2007; 56:1283-1290.